Key FDA Marijuana Response, MMJ International Holdings Advances Cannabis-Derived Therapeutics for Huntington’s Disease
MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has ...
FiercePharma5h
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now ...
Neurocrine stock target cut to $185 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $185 from the previous $190 while maintaining a Buy rating on the stock. This revision follows ...
Sickle cell disease is a genetic disorder that causes lifelong suffering – here’s what you need to know
Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...
The Physicians Really Are Healing Themselves, With Ozempic
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...